DURHAM, N.C., and LIEGE, Belgium--(BUSINESS WIRE)--MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced the results from a collaborative study demonstrating that changes in DNA methylation patterns in adjacent benign tissue could predict the presence of prostate cancer not detected or missed using standard histopathology. An underestimation of prostate cancer stage or grade can result from errors in biopsy tissue sampling. Such underestimates are of concern due to vastly increased enrollment in Watchful Waiting Active Surveillance (WWAS) programs to avoid unnecessary radical therapy. The reported methylation patterns act as so-called “field cancerization effect” biomarkers to detect prostate cancer missed due to biopsy sampling errors. The presentation of this important new prostate cancer data at the American Urology Association (AUA) Annual Meeting in Washington DC by Dr. Sandra Gaston of Beth Israel Deaconess Medical Center resulted from a collaborative effort between MDxHealth, Beth Israel Deaconess, Harvard Medical School, the New England Baptist Hospital, and the NCI’s Early Detection research Network (EDRN). The AUA 2011 Annual Meeting takes place May 14-19, at the Walter E. Washington Convention Center, in Washington, DC.
